Arbutus Biopharma
ABUS
ABUS
111 hedge funds and large institutions have $215M invested in Arbutus Biopharma in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 34 increasing their positions, 29 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
17% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 29
12% more funds holding
Funds holding: 99 → 111 (+12)
8.94% more ownership
Funds ownership: 42.28% → 51.22% (+8.9%)
Holders
111
Holding in Top 10
4
Calls
$4.66M
Puts
$3.94M
Top Buyers
| 1 | +$21.8M | |
| 2 | +$3.25M | |
| 3 | +$1.9M | |
| 4 |
CC
Centiva Capital
New York
|
+$873K |
| 5 |
State Street
Boston,
Massachusetts
|
+$588K |
Top Sellers
| 1 | -$628K | |
| 2 | -$537K | |
| 3 | -$316K | |
| 4 |
Citigroup
New York
|
-$294K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$211K |